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Background and purpose: Constitutive c-H2AX expression might indicate disruption of the DNA damage
repair pathway, genomic instability, or shortened telomeric ends. Here, we quantiﬁed expression of
endogenous c-H2AX and its downstream factor 53BP1 in a large number of breast cancer cell lines
(n = 54) and a node-negative breast cancer cohort that had not received adjuvant systemic treatment
(n = 122).
Materials and methods: Formalin ﬁxed parafﬁn embedded breast cancer cell lines and tumors were immu-
nohistochemically analyzed for c-H2AX and 53BP1 expression, and related to cell line, patient and tumor
characteristics and to disease progression.
Results: In breast cancer cell lines, c-H2AX positivity was associated with the triple negative/basal like
subgroup (p = 0.005), and with BRCA1 (p = 0.011) or p53 (p = 0.053) mutations. Speciﬁcally in triple neg-
ative breast cancer patients a high number of c-H2AX foci indicated a signiﬁcantly worse prognosis
(p = 0.006 for triple negative vs. p = 0.417 for estrogen receptor (ER), progesterone receptor (PR) or
HER2 positive patients). A similar association with disease progression was found for 53BP1. In a multi-
variate analysis with tumor size, grade, and triple negativity, only the interaction between triple negativ-
ity and c-H2AX remained signiﬁcant (p = 0.002, Hazard Ratio = 6.77, 95% CI = 2.07–22.2).
Conclusions: Constitutive c-H2AX and 53BP1 staining reveals a subset of patients with triple negative
breast tumors that have a signiﬁcantly poorer prognosis.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 101 (2011) 39–45The DNA damage repair pathway is activated upon damage to
DNA caused by a plethora of causes such as ionizing radiation, hy-
poxia, reactive oxygen species, and certain chemicals, as well as
replicational or transcriptional errors [1]. Several types of damage
can occur, including double stranded breaks (DSBs) in which both
DNA strands have been cleaved. If left unrepaired, DSBs are lethal
for the cell [2,3]. One of the ﬁrst events in reaction to activation of
the DNA damage repair pathway is phosphorylation of histone
H2AX on serine 139 on each side of the break, yielding c-H2AX foci
[4–7]. c-H2AX recruits other factors such as 53BP1, BRCA1, MDC1,
and the MRE11-RAD50-NBS1 (MRN) complex to sites of damage
[8–12]. Unrepaired DSBs, indicated by retention of irradiation in-
duced c-H2AX foci, have predictive value in tumors as a biomarker
for sensitivity to radiotherapy [13].f Radiation Oncology 874,
ox 9101, 6500 HB Nijmegen,
der the Elsevier OA license.Constitutive, endogenous c-H2AX foci are rare in normal
primary human cells and tissues [14]. However, tumor cells show
different degrees of constitutive phosphorylated H2AX in the
absence of exogenously induced DSBs [14]. Cell lines with more
endogenous foci exhibit more chromosomal instability than those
with fewer endogenous foci [15]. Colocalization of endogenous foci
with other DNA repair factors (e.g. 53BP1, MRN-complex) seems to
indicate that actual DNA repair is taking place at these sites
[16,17]. Endogenous expression of c-H2AX has not only been
observed in tumor cell lines, but also in cancer tissues and even
in their precursor lesions, suggesting a role for activated DNA
damage repair in tumorigenesis [18,19]. Data from recent studies
indicate that the endogenous expression of DNA damage response
factors may also be associated with damaged, shortened telomeres
[20–22] or hypoxia [23].
Recently, an association between c-H2AX expression, and
BRCA1 mutation status and triple negativity has been found in a
cohort of breast cancers [24]. Whether endogenous expression of
c-H2AX is consequential in breast cancer has, to the best of our
knowledge, not been described. In the current study the constitu-
40 c-H2AX expression in breast cancertive expression of c-H2AX and its downstream factor 53BP1 were
examined in breast cancer cell lines and breast cancer tissues
and correlated with clinicopathological parameters and outcome.Materials and methods
Tumor arrays
A breast cancer cell microarray of 54 breast cancer cell lines in
triplicate was constructed as described previously [25]. A tumor
microarray was constructed from formalin ﬁxed parafﬁn embed-
ded breast tumors [26]. Tumor cores were marked on hematoxylin
and eosin-stained slides by a pathologist. Two millimeter diameter
punches were made with a Tissue-Tek Quick Ray puncher (Sakura
Inc.) and embedded in fresh parafﬁn.Patients
Breast cancer patients were selected from a cohort surgically
treated between January 1991 and December 1996 that had no ax-
illary lymph node invasion, received no adjuvant systemic treat-
ment, and had at least 5 years follow up or an earlier recurrence
during follow-up [26]. By enriching for triple negative tumors, in
order to obtain approximately equal sized groups of breast cancer
subtypes, the selection criteria led to a patient cohort (n = 122)
with 25% ER positive, 13% PR positive, 30% HER2-positive, and
44% triple negative patients. As approved by the institutional re-
view board and according to national law, coded tumor tissues
were used.Immunohistochemical staining of formalin ﬁxed parafﬁn embedded
tissue sections
Sections were stained as described previously [27] with minor
modiﬁcations. For c-H2AX sections were rinsed in Tris BufferedFig. 1. Antibody validation for c-H2AX (a and b) and 53BP1 (c and d) in irradiated SCCNi
four hours after irradiation with 10 Gy foci are apparent (b and d). Original magniﬁcatioSaline (pH 7.4), and normal donkey serum was diluted in 1% BSA
in TBS with 0.2% Triton X-100 (Sigma–Aldrich, St. Louis, MO,
USA). The primary antibodies used were rabbit anti-phospho-
H2AX (#2577, Cell Signaling Technology, Danvers, MA, USA) di-
luted 1:500 in TBS with 1% BSA and rabbit anti-53BP1 (210-419-
R050, Alexis Biochemicals Corporation, San Diego, CA, USA) diluted
1:5000. The secondary antibody was biotin-conjugated donkey
anti-rabbit IgG (711-066-152, Jackson) diluted 1:400 in TBS
(c-H2AX) or PBS (53BP1).Image acquisition, scoring procedure, and statistical analysis
All images were captured with a Leica DM 6000 microscope
using IP-lab imaging software (Scanalytics Inc., Fairfax, VA, USA).
Stained sections were viewed at a magniﬁcation of 200 and man-
ually scored by at least two independent researchers (A.N and S.K.
or P.S.) according to c-H2AX or 53BP1 staining intensity, where 0
indicates no staining present, 1 is light staining, 2 is moderate
staining, and 3 intense staining. Figs. 2 and 4 of the results section
show examples of the different staining intensities found.Statistical analyses
Statistical analyses were performed using SPSS 16.0 software
(SPSS Benelux BV, Gorinchem, The Netherlands). Differences in
staining intensities between patient subgroups were analyzed with
v2 tests and/or Spearman rank correlation tests. Disease progres-
sion was deﬁned as time between primary surgery and any recur-
rence (local or regional) or distant metastasis. Death by any cause
was treated as censoring event in Kaplan–Meier survival curves
with log-rank testing of differences in disease progression between
patient subgroups. Multivariate analyses were performed with Cox
Proportional Hazard modeling with backward selection of vari-
ables based on the Likelihood Ratio. A p < 0.05 was considered sta-
tistically signiﬁcant.j3 xenografts. Pre-irradiation a limited number of foci are present (a and c). Twenty-
n: 400, scale bar is 100 lm.
Fig. 2. Different staining intensities of c-H2AX in breast cancer cell lines, ranging from 0 to 3 (a–d). Depicted cell lines are: MDA-MB-175VII (a), EVSA-T (b), BT-20 (c), and
MDA-MB-435s (d). Original magniﬁcation: 400, scale bar is 100 lm.
Fig. 3. Differences in cell lines with different c-H2AX staining intensities and characteristics as fraction of cell lines positive for: (a) triple negativity (p = 0.005), (b) estrogen
receptor (p = 0.001), (c) BRCA mutations (p = 0.011), and (d) p53 mutations (p = 0.053).
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Fig. 4. Differences in c-H2AX and 53BP1 expression in breast tumors. Typical examples of tumors with scores from 0 to 3 are shown. Original magniﬁcation: 400, scale bar
is 100 lm.
Table 1
Patient characteristics of low versus high c-H2AX expression in triple negative and any receptor positive breast cancer patients.
Triple negative Any receptor positive
c-H2AX Low High p Low High p
Total n 30 12 39 15
Mean age 57 51 0.341 59 49 0.011
pT 1 13 7 0.648 18 11 0.359
2 14 5 19 4
3 2 0 2 0
4 1 0 0 0
pN 0 30 12 – 39 15 –
1 0 0 0 0
M 0 30 12 – 39 15 –
1 0 0 0 0
Menopausal state Pre 10 5 0.611 6 7 0.023
Post 20 7 33 8
Grade I 0 0 0.783 1 1 0.717
II 4 2 10 4
III 18 8 18 8
Unknown 8 2 10 2
Tumor type Ductal 23 11 0.136 31 13 0.867
Lobular 2 0 4 1
Other 5 1 4 1
Surgery Mastectomy 17 1 0.021 19 5 0.263
Lumpectomy 13 11 20 10
Adjuvant radiotherapy No 18 1 0.003 17 3 0.155
Yes 12 11 22 12
ER Negative 30 12 – 18 9 0.202
Positive 0 0 21 6
PR Negative 30 12 – 28 12 0.449
Positive 0 0 11 3
HER2 Negative 30 12 – 17 4 0.119
Positive 0 0 22 11
42 c-H2AX expression in breast cancerResults
c-H2AX and 53BP1 antibody validation
The c-H2AX and 53BP1 antibodies used in this study were val-
idated on irradiated xenografted head and neck squamous cell car-
cinoma tissues. Formalin ﬁxed parafﬁn embedded SCCNij3 tumors
were available from previous studies [28,29]. c-H2AX and 53BP1
staining on normal tissue of the breast, kidney, liver and lung
showed no noteworthy expression. After a dose of 10 Gy the
SCCNij3 tumors showed increased c-H2AX and 53BP1 foci forma-tion (Fig. 1), indicating that the antibody and staining procedures
were valid.Endogenous c-H2AX expression in a large panel of breast cancer cell
lines
A microarray containing cores of 54 different breast cancer cell
lines, embedded in triplicate, was stained for c-H2AX and subse-
quently scored. Examples of different staining intensities are
shown in Fig. 2. Scores were correlated with known characteristics
Fig. 5. Association of c-H2AX and 53BP1 with disease progression. (a) No association of low c-H2AX (black line) or high c-H2AX (dotted line) staining intensity in receptor
(ER, PR, and/or HER2) positive tumors was found (n = 54) but in triple negative tumors (n = 42) high c-H2AX leads to a signiﬁcantly shorter disease free interval (p = 0.006, b).
(c) No association of low 53BP1 (black line) or high 53BP1 (dotted line) was found in receptor positives (n = 61), but in triple negatives (n = 49) high 53BP1 leads to a decrease
in disease free interval (p = 0.029, d). Patient numbers between c-H2AX and 53BP1 may differ due to loss of patient samples during the staining procedure.
A. Nagelkerke et al. / Radiotherapy and Oncology 101 (2011) 39–45 43of the cell lines [25]. c-H2AX positivity was associated with the tri-
ple negative/basal like subgroup (p = 0.005), estrogen receptor neg-
ativity (p = 0.001) and with BRCA1 (p = 0.011) or p53 (p = 0.053)
mutations (Fig. 3).Expression of c-H2AX and 53BP1 in breast tumors
Next, the expression ofc-H2AXand53BP1was analyzed in a het-
erogeneous group of 122 non-adjuvantly treated patients with
breast cancers. The range of staining intensities for both markers is
shown in Fig. 4. The c-H2AX staining was found to be negative in
35% of the cases and highly positive in 8% of the cases. No signiﬁcant
correlation was found between c-H2AX expression and hormone
receptor status. In addition, 53BP1 was stained on consecutive sec-
tions of the breast cancer tissue microarray. Similar to c-H2AX, dif-
ferent patterns of staining intensity of 53BP1 were observed (see
Fig. 4). Scores for c-H2AX and 53BP1 showed a strong correlation
(p < 0.001), although 53BP1 showed a higher number of positive tu-
mors: 14% of the cases were negative and 32% of the cases were
scored as strongly positive. In the receptor positive group young
age (p = 0.011) and premenopausal status (p = 0.023) were associ-
ated with stronger c-H2AX staining (Table 1). In the triple negative
patients, stronger c-H2AX stainingwas found in patients eventually
treatedwith lumpectomyvsmastectomy(p = 0.021) andwith (post-
surgical) adjuvant radiotherapy (p = 0.003).Expression of c-H2AX and 53BP1 has prognostic relevance in triple
negative breast cancers
Next, the relation between c-H2AX and disease progression was
evaluated. Due to the small sample size, staining scores of 0 and 1 aswell as 2 and3were taken together for this purpose. For the group as
a whole, no signiﬁcant associations with prognosis were found.
However, within the group of triple negative tumors a highly signif-
icant association with disease progression was found (p = 0.006,
Fig. 5a and b), which was absent in the hormone receptor positive
group. Similar resultswere found for 53BP1 (p = 0.029, Fig. 5c andd).
Within the triple negative breast cancers, a multivariate analy-
sis with surgery and radiotherapy, both with which c-H2AX was
associated (Table 1), revealed that c-H2AX remained a signiﬁcant
factor (p = 0.010; Hazard Ratio (HR) = 4.06, 95% CI = 1.40–11.77).
Thus, the prognostic relevance of c-H2AX in triple negative breast
cancers was independent of its association with these factors.
Next, we performed a multivariate Cox Regression analysis
including prognostically relevant parameters, i.e. tumor size, histo-
logical grade, and tumor type (triple negative, steroid hormone,
and/or HER2 positive). All patients were node negative and did
not receive adjuvant systemic treatment, thus these parameters
were not entered in the model. In addition, an interaction variable
for triple negativity and c-H2AX was entered in the model, which
would indicate whether the prognostic value of c-H2AX was differ-
ent in these tumors. Only this interaction between triple negativity
and c-H2AX remained signiﬁcantly associated with disease pro-
gression (p = 0.002, HR = 6.77, 95% CI = 2.07–22.2) after correction
for tumor size, grade, and triple negativity.Discussion
Here, we found that constitutive c-H2AX expression is higher in
triple negative, and in BRCA1 and p53 mutated breast cancer
cell lines. In addition, endogenous c-H2AX and 53BP1 expression
in breast cancer tissue was evaluated and correlated with
44 c-H2AX expression in breast cancerclinicopathological parameters and outcome in a human breast can-
cer patient cohort. It has been reported that triple negative breast
cancers display more endogenous c-H2AX expression [24] and that
this subset of cancers has a higher incidence of carrying aberrations
in components of the DNA damage repair pathway [24,30]. In the
current study a correlation between c-H2AX expression and triple
negativity was found in a group of breast cancer cell lines, but this
association could not be conﬁrmed in breast cancer patients. Fur-
ther, basal like and/or triplenegative tumorsareknowntohavea lar-
ger number of BRCA1mutation carriers, which previously have been
associated with a higher occurrence of c-H2AX positivity [24]. The
BRCA-status of the patients included in the current study, however,
is unknown. Nevertheless, we did ﬁnd that in breast cancer patients
high endogenous c-H2AX or 53BP1 expression revealed a subset of
triplenegative tumorswithpoorprognosis. Our results seemto indi-
cate that triple negative and/or basal like breast tumors represent a
fundamentally different subgroup of tumors where apparently
endogenous c-H2AX expression has relevance for disease progres-
sion, although this should be validated in independent, unselected
larger breast cancer patient cohorts.
Several studies have attempted to elucidate the exact identity of
the endogenous c-H2AX foci observed in many different cancerous
lesions and whether they are associated with actual DNA damage.
Recruitment of other downstream DNA damage repair factors to
these foci has led to the idea that actual DNA repair is attempted at
these sites [16,17]. One recent explanation for the occurrence of
endogenous c-H2AX in cancers is the association with telomeres,
protective structures which form the chromosome ends in eukary-
otes. Duplication of DNA results in shortened telomeres after every
cell cycle. Shortening of telomeres and activation of telomerase, an
enzyme necessary for telomere lengthening, occurs frequently in
(pre-)cancerous lesions [31–35]. Normally, telomere shortening is
a signal for replication arrest and replicative senescence. In the ab-
senceof a telomeric structure, chromosomeends arehighlyunstable
and are prone either to degradation, merging with other chromo-
somes (genomic instability) or DNA double stranded breaks
[20,21]. Nakamura et al. showed that a considerable number of
endogenous c-H2AX foci do not represent actual double stranded
breaks but are in fact uncapped telomeres [22]. Thus, telomere dys-
function can lead to DNA damage and phosphorylation of H2AX at
these sites [36,37]. In addition, telomere associated chromosomal
rearrangementsmay lead to a tumor phenotypewith the associated
immortality and unlimited replicative potential [38]. However, at
the moment it is unclear what endogenous c-H2AX and 53BP1
expression represents in our patients. The mechanism behind the
occurrence of these foci and the relation with disease progression
and/or treatment sensitivity remain to be elucidated.
In conclusion, in the current breast cancer cohort an association
was found between expression of the DNA damage repair factors
c-H2AX and 53BP1 and disease progression in triple negative pa-
tients. Independent validation of this ﬁnding is necessary in larger
unselected breast cancer patient cohorts, and further studies in
breast cancers from germline BRCA1 mutation carriers and by cor-
relating c-H2AX expression directly to telomere length should be
performed to determine the nature of these foci.
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